EASL is launching a new educational activity called EASL Molecular Tumour Boards (EASL-MTB) comprised of a multidisciplinary panel of experts. The main purpose of this activity is to educate physicians and health allies on precision oncology based on molecular data in primary liver malignancies.
This EASL-MTB will be discussing clinical cases of intrahepatic cholangiocarcinoma (CCA) with Target Enrichment Sequencing (TES) results and allocation of treatment. CCA is a rare cancer type that develops in the biliary tree. Often silent and asymptomatic, these tumours are very aggressive, highly heterogeneous, chemoresistant, and their incidence is increasing worldwide. Due to the intrinsic tumour characteristics, efficacy of the current treatment options is compromised and CCA remains a highly lethal disease.
You will be able to address questions through Q&A during the liver webinar or through the chat function below.
Register now for free for the first EASL molecular Tumour Board on intrahepatic cholangiocarcinoma scheduled on Tuesday 23 May 18:00 CET.